Floatz Rating
BB65/100
Confidence
Indicative
Sponsor
Mayo Clinic
Modality
protein_peptide
Development Phase
Phase 3
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
50High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT02444546CT.gov Wild-Type Reovirus in Combination With Sargramostim in Treating Younger Patients With High-Grade Relapsed or Refractory Brain Tumors | — | Completed | — | — | — |
NCT00052780CT.gov Temozolomide and O6-Benzylguanine in Treating Children With Recurrent Brain Tumors | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Childhood Medulloblastoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Nivestim (this asset) | Mayo Clinic | P3 | BB · 65 |
| Irinotecan | National Cancer Institute (NCI) | P2 | BB |
| Nogitecan | City of Hope Medical Center | P2 | BB |
| 2 (1H))-QUINOLINONE,6-(AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL)-4-(3-CHLOROPHENYL)-1-METHYL-,(+)- | National Cancer Institute (NCI) | P2 | B |
| Edotreotide | Sue O'Dorisio | P2 | CCC |
| Vorinostat | National Cancer Institute (NCI) | P1 | CCC |
| Pan-Fgfr Tyrosine Kinase Inhibitor Jnj-42756493 | National Cancer Institute (NCI) | P2 | CCC |
| Romidepsin | City of Hope Medical Center | P1 | CCC |
| Lapatinib | National Cancer Institute (NCI) | P1/2 | CCC |
+18 more in the Childhood Medulloblastoma cohort
Other indications for Nivestim
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Burkitt Lymphoma | — | P4 | BBB · 78 |
| Neutropenia | — | P4 | BBB · 76 |
| Mycosis Fungoides | — | P4 | BBB · 75 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Nivestim in Childhood Medulloblastoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/n-met-g-csf-childhood-medulloblastoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →